USBiomaterials ("USB") develops products that restore tissue structure and function, leveraging a single proprietary science platform into three different product development categories. This science platform is a series of inorganic, bioactive material formulations - composed entirely of elements naturally occurring in body chemistry -- that release ions into local body environments in concentrations needed to facilitate key biological processes at that site. The Company has already commercialized products in one of the three platforms, thereby demonstrating FDA approvability, safety and efficacy, and the Company's ability to execute its plans. This first platform is bone graft substitutes (NovaBone® and PerioGlas®) that offer a more natural regeneration response than "growth factors", but with similar stimulatory effects. USB is developing products for its second platform (NovaMin (tm)) - a tooth remineralizer that is safer and works faster and in a broader range of situations than the current standard of fluoride. Significant commercial alliances for this are already in place, with more in late-stage negotiation. The Company is also confirming proof-of-concept for its third platform ("CSM Technology"), which offers localized anti-inflammatory (anti-TNF) effects, with target applications for inflammatory skin conditions (i.e. psoriasis) and post-surgical inflammatory complications. Beyond a versatile, well-documented core technology, USB has extensive corporate capabilities and resources as well: USB's headquarters and research labs in Gainesville, Florida house a technical staff with extensive experience combining the materials sciences and life sciences. The company maintains research relationships with several universities including the University of Florida, University of Maryland and Imperial College (U.K.). The company has a well-developed regulatory affairs capability and has received clearances for products in over 25 nations, including the U.S., Canada, the European Community countries, and China. This combination of a dynamic, well documented core technology with multiple opportunities for commercial success and solid corporate capabilities for additional research and commercialization offers USBiomaterials Corporation an exciting future
